BiotechTube

LY3537021 + Placebo + Standard of Care Antiemetic Therapies + Background Chemotherapy

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nausea

Conditions

Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms

Trial Timeline

Nov 28, 2025 → Sep 1, 2026

NCT ID
NCT07169851

About LY3537021 + Placebo + Standard of Care Antiemetic Therapies + Background Chemotherapy

LY3537021 + Placebo + Standard of Care Antiemetic Therapies + Background Chemotherapy is a phase 2 stage product being developed by Eli Lilly for Nausea. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07169851. Target conditions include Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07169851Phase 2Recruiting

Competing Products

20 competing products in Nausea

See all competitors
ProductCompanyStageHype Score
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
85
Sancuso + IV granisetronKyowa KirinPhase 1
33
granisetron transdermal system + Granisetron IVKyowa KirinPhase 1
33
palonesetronEisaiPhase 2
52
Ondansetron + PalonosetronEisaiPhase 2
52
GranisetronKyowa KirinPhase 3
77
Sancuso + IV granisetronKyowa KirinPhase 1
33
DroperidolKyowa KirinApproved
85
esomeprazoleAstraZenecaPhase 3
77
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
52
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue TherapyMerckPhase 3
77
Aprepitant + Aprepitant Placebo + Ondansetron + Dexamethasone + Ondansetron Placebo + Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).MerckApproved
85
Dexamethasone + Aprepitant + Placebo DexamethasoneMerckPre-clinical
23
Comparator: MK0517 + Comparator: ondansetronMerckPhase 3
77
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
85
FosaprepitantMerckPhase 2
52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonistMerckPhase 3
77
Aprepitant + ScopolamineMerckPre-clinical
23
Fosaprepitant + Dexamethasone + 5HT3MerckPhase 2
52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasoneMerckPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85